Or Akiva, Israel

Regentis Biomaterials

www.regentis.co.il
Or Akiva, Israel
SEARCH FILTERS
Time filter
Source Type

Patent
Regentis Biomaterials | Date: 2017-03-15

The present invention relates to scaffolds composed of a protein backbone cross-linked by a synthetic polymer. Specifically, the present invention provides PEGylated-thiolated collagen scaffolds and PEGylated albumin scaffolds and methods of generating and using same for treating disorders requiring tissue engineering.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: NMP.2010.2.3-1 | Award Amount: 14.80M | Year: 2012

The development of functional materials for tissue regeneration is today mostly based on perceived and limited design criteria often using a single point approach with lengthy animal trials. The outcome after in-vitro and in-vivo evaluation is often disappointing resulting in a tedious iteration process. The main objective of this project is to achieve radical innovations in state-of-the-art biomaterials and to design highly performing bioinspired materials learning from natural processes. By this outcome driven project comprising first class academic and industrial participants the project will create scientific and technical excellence and through links with these SMEs will strengthen the technological capacity and their ability to operate competitively on an international market. BIODESIGN will (i) perform a careful retrospective-analysis of previous outcomes from clinical studies performed with humans through animal modelling in a reverse engineering approach applied to an in-vitro to the molecular design level, (ii) develop new strategies for a more rational design of ECM mimetic materials serving both as gels and load carrying scaffolds, (iii) link novel designs to adequate and more predictive in-vitro methods allowing significant reduction in development time and use of animals and (iv) evaluate these concepts for musculoskeletal and cardiac regeneration. By the development of safe, ethically and regulatory acceptable, and clinically applicable materials this project will promote harmonization while at the same time creating awareness in society of the benefits of these innovations as one of the key points is to improve health and quality of life of the patients. BIODESIGN will stimulate technological innovation, utilization of research results, transfer of knowledge and technologies and creation of technology based business in Europe. It will also support the development of world-class human resources, making Europe a more attractive to top researchers.


Patent
Regentis Biomaterials | Date: 2015-04-06

Apparatus and methods are described, including apparatus for treating a cavity in a human body, the apparatus including a delivery tube. A barrier device has a collapsed and an expanded configuration, the barrier device moving from the collapsed to the expanded configuration upon being deployed from the delivery tube. A pushing element, slidably disposed within a lumen of the delivery tube, deploys the barrier device from the delivery tube by pushing the barrier device. One or more barrier-deployment elements are coupled to the barrier device and to the pushing element, the barrier-deployment elements being configured to conformingly contact the barrier device with tissue surrounding the cavity. The barrier device is configured to isolate the cavity from surrounding body fluid that is between the barrier device and the pushing element, following deployment of the barrier device from the delivery tube. Other applications are also described.


Patent
Regentis Biomaterials | Date: 2014-10-13

The present invention relates to biodegradable scaffolds composed of a naturally-occurring protein backbone cross-linked by a synthetic polymer. Specifically, the present invention provides PEGylated-fibrinogen scaffold and methods of generating and using same for treating disorders requiring tissue regeneration.


Patent
Regentis Biomaterials | Date: 2014-10-06

Apparatus and methods are described, including apparatus for treating a cavity in a human body, the apparatus including a delivery tube. A bather device has a collapsed configuration and an expanded configuration, the barrier device moving from the collapsed configuration to the expanded configuration upon being deployed from the delivery tube. A pushing element, slidably disposed within a lumen of the delivery tube, is configured to deploy the barrier device from the delivery tube by pushing the bather device. One or more bather-deployment elements are coupled to the barrier device and to the pushing element, the bather-deployment elements being configured to conformingly contact the barrier device with tissue surrounding the cavity. Other applications are also described.


Patent
Regentis Biomaterials | Date: 2016-09-08

The present invention relates to biodegradable scaffolds composed of a naturally-occurring protein backbone cross-linked by a synthetic polymer. Specifically, the present invention provides PEGylated-fibrinogen scaffold and methods of generating and using same for treating disorders requiring tissue regeneration.


Patent
Regentis Biomaterials | Date: 2012-09-12

The present invention relates to a polymer-protein precursor molecule comprising albumin and at least two synthetic polymers covalently attached to said albumin, each of said at least two synthetic polymers having a functional group, said functional group being selected capable of cross-linking with a functional group of at least one other synthetic polymer, said at least one other synthetic polymer forming a part of at least one other polymer-protein precursor molecule at least one other polymer-protein precursor molecule which comprises albumin and at least two synthetic polymers covalently attached to said albumin, said cross-linking forming a scaffold.


A method of treating a disorder characterized by tissue damage is provided. The method comprising providing to a subject in need-thereof a composition which comprises a synthetic polymer attached to denatured fibrinogen or a therapeutic portion of the fibrinogen, the composition being formulated for releasing the therapeutic portion of the fibrinogen in a pharmacokinetically regulated manner, thereby treating the disorder characterized by tissue damage or malformation.


A pharmaceutical, cosmetic or cosmeceutical composition which exhibits a reverse thermal gelation is disclosed herein, as well as a composition-of-matter comprising a cross-linked form of the composition, and a process for producing the composition-of-matter. The composition is characterized as exhibiting a shear storage modulus of at least 100 Pa at temperatures in a range of from 17 C. to 21 C., and a shear storage modulus of less than 100 Pa at a temperature of 4 C., and as being curable in a physiological medium, and/or comprises a polymer-polypeptide conjugate comprising a polypeptide having attached thereto at least two polymeric moieties, wherein at least one of said polymeric moieties further comprises at least one polymerizable group; a poloxamer; and a poloxamer substituted by at least one polymerizable group. Further disclosed herein are uses of the composition and/or composition-of-matter in the treatment of tissue damage or loss.


Conjugates are provided herein which comprise a protein attached to at least two polymeric moieties, at least one of which exhibits reverse thermal gelation. The conjugates are suitable for being cross-linked by non-covalent and/or covalent cross-linking. Compositions-of-matter comprising cross-linked conjugates are provided herein, as well as processes for producing same. Methods of controlling a physical property of compositions-of-matter are also provided herein. The conjugates and compositions-of-matter may be used for various applications, such as cell growth, tissue formation, and treatment of disorders characterized by tissue damage or loss, as described herein.

Loading Regentis Biomaterials collaborators
Loading Regentis Biomaterials collaborators